BRD7389 Reference: 20214-5 An inhibitor of RSKs (IC50s = 1.5, 2.4, and 1.2 μM for RSK1, RSK2, and RSK3, respectively); causes mouse αTC1 pancreatic α cells to adopt several morphological and gene expression features of β cells, including increased insulin expression
SR 3576 Reference: 20215-1 A JNK3 inhibitor (IC50 = 7 nM); selective for JNK3 over JNK1 and p38 MAP kinase (IC50s = 0.17 and >20 µM, respectively); inhibits c-Jun phosphorylation in INS-1 cells (IC50 = 1.3 µM)
SR 3576 Reference: 20215-5 A JNK3 inhibitor (IC50 = 7 nM); selective for JNK3 over JNK1 and p38 MAP kinase (IC50s = 0.17 and >20 µM, respectively); inhibits c-Jun phosphorylation in INS-1 cells (IC50 = 1.3 µM)
Terazosin (hydrochloride) Reference: 20216-1 A potent and selective α1-AR antagonist; selective for α1-AR (Kis = 3.28, 0.68, and 1.09 for α1A-, α1B- and α1D-ARs, respectively) over α2-AR subtypes (Kis = 1,510, 7.71, and 78.2 nM for A2a-, A2b-, and A2c-ARs, respectively); decreases blood pressure in spontaneously hypertensive rats when administered at 0.1-30 mg/kg
Terazosin (hydrochloride) Reference: 20216-100 A potent and selective α1-AR antagonist; selective for α1-AR (Kis = 3.28, 0.68, and 1.09 for α1A-, α1B- and α1D-ARs, respectively) over α2-AR subtypes (Kis = 1,510, 7.71, and 78.2 nM for A2a-, A2b-, and A2c-ARs, respectively); decreases blood pressure in spontaneously hypertensive rats when administered at 0.1-30 mg/kg
Terazosin (hydrochloride) Reference: 20216-250 A potent and selective α1-AR antagonist; selective for α1-AR (Kis = 3.28, 0.68, and 1.09 for α1A-, α1B- and α1D-ARs, respectively) over α2-AR subtypes (Kis = 1,510, 7.71, and 78.2 nM for A2a-, A2b-, and A2c-ARs, respectively); decreases blood pressure in spontaneously hypertensive rats when administered at 0.1-30 mg/kg